CERo Therapeutics [CERO] - Last Close: $2.55
This tiny biotech is skyrocketing after publishing promising clinical research supporting CER-1236 as a treatment for leukemia patients.
CERo outlined its findings in a paper titled Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia (AML) published in Clinical Cancer Research medical journal.
The study found that CER-1236 “ effectively eliminated leukemic cells in the company’s experiments.“
CERo says its findings support a Phase 1 trial for AML and, potentially, additional therapeutic options for the drug.
CERO is up 668.2% on almost a million shares traded.
My Take: CERO is seeing enormous gains as a result of this news, but it almost seems too good to be true. Watch for a pull back.
Lytus Technologies [LYT] - Last Close: $2.31
After Wednesday’s close, Lotus Technologies announced the launch of a suite of cloud infrastructure services it’s calling the Lytus Cloud.
The company says the announcement marks their entrance into the “$326 billion data center market.”
LYT is soaring in today’s premarket. It’s up 208.2% on roughly 5 million shares traded.
My Take: LYT has a very high short ratio, so I suspect this move is more the result of a short squeeze than the aforementioned news.
Brera Holdings [BREA] - Last Close: $1.02
A recent regulatlory disclosure revealed that Brera’s executive chairman and veteran investment banker Daniel McClory has acquired a majority stake.
According to the filing, McClory recently acquired 4.6 million shares of stock, bringing his total ownership stake to nearly 55%.
He also controls 84% of the company’s total votes.
BREA is up 124.5% on over 15 million shares traded.
My Take: McClory’s buying spree could indicate he has plans for BREA. Investors could be positioning themselves for a potential buyout or take-private deal sometime in this stocks future.
Immuron [IMRN] - Last Close: $1.65
Positive interim top-line data from a Phase 2 trial of IMM-124E (Travelan®) is lifting shares of this tiny biotech this morning.
Immuron said the trial produced statistically significant results in several key categories, and the data supports advancement to a Phase 3 trial.
The company will now hold an end-of-Phase 2 meeting with the FDA to discuss the pivotal Phase 3 registration strategy and clinical trial plans.
IMRN is a top mover with a 94.2% gain on roughly 6 million shares traded.
My Take: IMRN looks like it’s on its way to an approval, but it could take a while for the next catalyst to develop.
